Name: 글로벌 시장 동향
SKU: PH76
Availability: InStock

보고서 요약(국문)

시장 개요
세계 골다공증 치료제 시장은 2022년 140억 6,640만 달러에 달했으며, 2030년까지 193억 3,660만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 세계 골다공증 치료제 시장은 예측 기간(2023~2030년) 동안 연평균 4.1%의 성장률을 기록할 것으로 전망됩니다.
세계 골다공증 치료제 시장의 성장은 생리 후 골다공증의 유병률 증가, 치료제 파이프라인의 확대, 바이오제약 회사의 투자 증가, 조기 진단을 위한 더욱 정교한 진단법 개발 등의 요인에 기인합니다.
또한, 골다공증 치료제 연구 증가, 신약 승인 건수 증가, 고령 인구 증가, 새로운 첨단 치료법 개발 등이 시장 성장을 촉진하고 있습니다.

시장 동향
생명공학 및 제약 회사의 연구 개발 투자 증가가 골다공증 치료제 시장 성장을 견인
골다공증 치료제에 대한 연구 증가, 주요 생명공학 회사의 투자 확대, 고령 인구 증가, 그리고 새롭고 혁신적인 첨단 기술 치료법의 등장 등이 모두 세계 골다공증 치료제 시장 성장에 기여하고 있습니다.
예를 들어, 2023년 4월, 반 안델 연구소(Van Andel Research Institute)는 골밀도 감소에 영향을 미치는 중요한 요인을 발견했다는 보고서를 발표했습니다. 이 발견은 골다공증 여성에게 부작용이 적으면서도 더 효과적인 치료제 개발로 이어질 수 있습니다.
연구에 따르면, KDM5C라는 후성유전적 조절인자가 결핍되었을 때 쥐의 골량이 유지되는 것으로 나타났습니다. KDM5C는 후성유전적 "표지"를 변화시켜 DNA의 지시가 적절한 시기와 위치에서 사용되도록 하는 "켜짐" 및 "꺼짐" 스위치와 유사한 기능을 합니다.

임상 시험 증가와 고령 인구 증가로 제조업체에 수익성 높은 기회 창출
주요 기업들이 최첨단 기술 개선을 위한 연구 개발 역량 강화 및 임상 시험에 상당한 투자를 진행함에 따라 시장 기회가 확대되고 있습니다. 또한, 고령 인구의 골다공증 치료 수요 증가도 시장 성장에 영향을 미치는 요인입니다. 2021년 미국 인구 조사에 따르면, 미국 인구의 16.8%인 5,589만 2,014명이 65세 이상이었습니다.
더불어 연구자들은 골다공증 치료를 위한 다양한 임상 시험을 진행하고 있습니다. Radius Health, Inc.의 발표에 따르면, 2022년 10월, 아발로파라타이드와 위약을 비교한 남성 골다공증 치료를 위한 3상 임상시험(NCT03512262)에서 얻은 데이터가 Journal of Bone and Mineral Research에 게재되었습니다.
TYMLOS(아발로파라타이드)라는 인체 부갑상선 호르몬 연결 펩타이드 유사체는 이미 골절 위험이 높은 폐경 후 여성 골다공증 치료제로 승인되었습니다.
골다공증 치료제의 낮은 치료율이 시장 성장을 저해할 것입니다.
그러나 전 세계 골다공증 치료제 시장은 고가의 신약, 후기 임상 단계에서의 탐색적 후보 물질 개발의 어려움, 그리고 골다공증 치료를 위한 골다공증 치료제의 낮은 치료율로 인해 향후 성장이 제한될 수 있습니다.

미국에서 경제적 보험에 가입된 환자 중 골다공증의 심각한 부작용 중 하나인 고관절 골절을 겪은 환자 10명 중 1명 미만이 골절 발생 후 첫 2분기 동안 골다공증 관련 치료를 받았다는 연구 결과가 내분비학회 연례 학술대회인 ENDO 2021에서 발표되었습니다. 이러한 요인들은 예상 기간 동안 시장 확장을 저해합니다.
COVID-19 영향 분석
COVID-19 분석에는 COVID-19 이전 시나리오, COVID-19 시나리오, COVID-19 이후 시나리오 외에도 가격 변동(팬데믹 기간 및 이후의 가격 변화를 COVID-19 이전 시나리오와 비교 평가), 수요-공급 스펙트럼(거래 제한, 봉쇄 및 그 이후 문제로 인한 수요와 공급의 변화), 정부 정책(정부 기관의 시장, 산업 또는 부문 재활성화 정책), 제조업체 전략 계획이 포함됩니다.

러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 세계 골다공증 치료제 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재 수출입은 예측 기간 동안 세계 골다공증 치료제 시장 성장에 거의 영향을 미치지 않을 것으로 전망됩니다.
세분화 분석
세계 골다공증 치료제 시장은 약물 종류, 제품 유형, 유통 채널 및 지역별로 세분화됩니다.
병원 약국은 병원 입원 환자 증가에 힘입어 유통 채널 부문에서 시장 점유율 42.1%를 차지합니다.
병원 약국의 궁극적인 목표는 환자의 약물 투여를 항상 유지하고 향상시키는 것입니다. 병원 약사의 주요 임무는 병원 및 기타 의료 시설에서 의약품 사용을 규제하는 것입니다. 처방, 구매, 유통, 모니터링 및 검토를 통해 환자의 치료 결과를 개선하는 것이 목표 중 하나입니다.

병원 약국은 환자에게 처방약 복용 방법을 교육하고, 응급 상황에서 약을 제공하며, 암 환자와 같은 특수 의료 치료를 지원하는 등 다양한 이점을 제공함으로써 수요 증가를 경험할 것입니다.
필요에 따라 병원 약국은 복용량 조절이나 약물 변경을 지원하고, 환자에게 적합한 약품을 찾아주고, 용기를 쉽게 읽고 열 수 있도록 하며, 골다공증과 관련 없는 잠재적인 건강 문제를 식별하는 데 도움을 줄 수 있습니다. 따라서 위에서 언급한 요인들은 병원 약국이 가장 큰 시장 점유율을 차지할 것임을 입증합니다.
지역 분석
북미는 주요 업체들의 강력한 입지와 기술 발전으로 인해 시장 점유율의 약 38.7%를 차지했습니다.
제조업체들은 북미 지역의 골다공증 치료제 수요 증가와 기술 발전으로 인해 사업 확장의 기회를 얻고 있습니다. 이 지역에는 많은 생산자와 공급업체가 있으며, 빠른 경제 발전으로 골다공증 치료제의 산업 생산이 증가하여 수요가 증가했습니다.

북미는 수많은 생산자와 공급업체를 보유하고 있으며, 이 지역의 빠른 경제 발전으로 산업 생산량이 증가하여 골다공증 치료제 수요가 급증하고 있습니다. 남녀 골다공증 환자를 위한 새로운 제품 출시가 증가함에 따라 시장 성장이 더욱 가속화될 것입니다.
또한 기술 발전, 규제 승인 및 신제품 출시가 시장 성장을 촉진하고 있습니다. 연구자들은 골다공증 진단 및 치료 접근법에 대한 인식이 높아지고 있으며, 이는 이 지역 시장 확대로 이어지고 있습니다. 이러한 요인들은 북미 시장의 지배력을 보여줍니다.
경쟁 환경
골다공증 치료제 시장의 주요 글로벌 기업으로는 F. Hoffmann-La Roche, Novartis AG, Merck & Co. Inc., Pfizer Inc., GSK Plc, Eli Lily and Co., Amgen Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd. 및 Radius Health Inc. 등이 있습니다.
보고서 구매 이유

보고서 구매 이유 • 약물 종류, 제품 유형, 유통 채널 및 지역별 글로벌 골다공증 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 골다공증 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 골다공증 치료제 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Osteoporosis Drugs Market reached US$ 14,066.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 19,336.6 million by 2030. The global osteoporosis drugs market is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030).
The global market for osteoporosis medications is expanding as a result of factors including the increasing prevalence of post menstruation osteoporosis, the growing size of the therapeutic pipeline, expenditures by biopharmaceutical companies and the creation of more sophisticated diagnostics for early detection.
The global osteoporosis drugs market is also expanding owing to the the increasing research studies for osteoporosis drugs, rising regulatory approvals for novel products, rising geriatric population, new novel technologically advanced therapies.
Market Dynamics
The Growing Investments in Research and Development by Biotechnology and Pharmaceutical Companies Drive the Growth of the Osteoporosis Drugs Market
The growing number of research studies on osteoporosis medicines, the growing investments by major biopharmaceutical companies, an increase in the population of older people, and new, innovative, technologically sophisticated therapies are all contributing to the growth of the global market for osteoporosis drugs.
For instance in April 2023, Van Andel Research Institute published a report which reported that the scientists have identified a crucial factor that contributes to decreased bone density; this finding may result in more effective medicines with fewer adverse effects for women with osteoporosis.
According to the research, mice's bone mass is preserved when an epigenetic modulator called KDM5C is lost. KDM5C functions by changing epigenetic "marks," which are similar to "on" and "off" switches that make sure the DNA instructions are used at the appropriate time and location.
Growing Clinical Trials and Rising Geriatric Population Creates Lucrative Opportunities for Manufacturers
Due to key players' significant investments for clinical trials in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for osteoporosis treatment is geriatric population. According to the 2021 American Community Survey, 16.8% of the country's population, or 55,892,014 persons, was 65 years of age or older.
Furthermore, researchers are conducting various clinical trials for osteoporosis treatment. In October 2022, data obtained from the Phase 3 Abaloparatide for the treating men with Osteoporosis clinical trial (NCT03512262) comparing abaloparatide to a placebo has been published in the Journal of Bone and Mineral Research, according to a statement from Radius Health, Inc.
A human parathyroid hormone-linked peptide analog called TYMLOS (abaloparatide) is already approved for the management of postmenopausal women with osteoporosis who are at a high risk of fracture.
A Low Rate of Treatment With Bone-Directed Medications will Hamper the Growth of the Market
The global marketplace for osteoporosis drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low rate of treatment with bone-directed medicines for osteoporosis disease.
Less than one in ten economically insured patients in the United States who got a hip fracture, one of the highly serious adverse effects of osteoporosis, obtained any osteoporosis medical treatment during the first two calendar quarters of their fracture, according to a study whose results were presented at the Endocrine Society's annual meeting, ENDO 2021. These factors prevent market expansion over the expected time period.
COVID-19 Impact Analysis
The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global osteoporosis drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global osteoporosis drugs market growth over the forecast period.
Segment Analysis
The global osteoporosis drugs market is segmented based on drug class, product type, distribution channel and region.
Hospital Pharmacy from Distribution Channel Segment Accounts for 42.1% of Market Share Owing to Rising Hospital Admissions
The ultimate objective of hospital pharmacy is to maintain and enhance patient drug administration at all times. Hospital pharmacists' primary duty is to regulate the use of medications in hospitals and other healthcare facilities. Through the prescription, purchasing, distribution, monitoring, and review of drugs, one of the objectives is to improve patient outcomes.
Hospital pharmacies will see an increase in demand benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.
If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use and making sure the container can be read and opened with ease. identifying potential health issues unrelated to osteoporosis. Hence above mentioned factors prove that hospital pharmacy will be the largest market shareholder.
Geographical Analysis
North America Accounted for Approximately 38.7% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements
Manufacturers have chances to expand their operations in this region because of the rising demand for osteoporosis drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of osteoporosis drugs, which has increased the demand.
North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of osteoporosis drugs. Rising new product launches for using in men and women with osteoporosis will drive the market growth.
Growth is also fueled by the rising technological advancements, regulatory approvals and novel product launches. Reseaerchers are becoming more aware of various kinds of diagnostics or treatment approaches for osteoporosis, leading to the expansion of the market in this region. These factors shows the dominance of North America.
Competitive Landscape
The major global players in the osteoporosis drugs market include F. Hoffmann-La Roche, Novartis AG, Merck & Co. Inc., Pfizer Inc., GSK Plc, Eli Lily and Co., Amgen Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd. and Radius Health Inc. among others.
Why Purchase the Report?
• To visualize the global osteoporosis drugs market segmentation based on drug class, product type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of osteoporosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global osteoporosis drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Product Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The growing investments in research and development by biotechnology and pharmaceutical companies
4.1.1.2. Increasing incidences of osteoporosis
4.1.2. Restraints
4.1.2.1. A low rate of treatment with bone-directed medications
4.1.3. Opportunity
4.1.3.1. Growing clinical trials and rising geriatric population
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Bisphosphonates *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. RANK Ligand Inhibitors
7.4. Selective Estrogen Receptor Modulators
7.5. Parathyroid Hormone Analog
7.6. Strontium
7.7. Calcitonin
7.8. Anti-Sclerostin
7.9. Others
8. By Product Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. Branded *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Generics
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
Australia
10.5.6.4. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. F. Hoffmann-La Roche *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Novartis AG
12.3. Merck & Co. Inc.
12.4. Pfizer Inc.
12.5. Eli Lilly and Co. (Lilly)
12.6. Amgen Inc.
12.7. Radius Health, Inc.
12.8. Teva Pharmaceutical Industries Ltd.
12.9. GSK Plc
12.10. AbbVie Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

F. Hoffmann-La Roche, 4.	Key Developments, Novartis AG, Merck & Co. Inc., Pfizer Inc., Eli Lilly and Co. (Lilly), Amgen Inc., Radius Health, Inc., Teva Pharmaceutical Industries Ltd., GSK Plc, AbbVie Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Osteoporosis Drugs Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Osteoporosis Drugs Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Osteoporosis Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Osteoporosis Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Osteoporosis Drugs Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Osteoporosis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 7 Global Osteoporosis Drugs Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Osteoporosis Drugs Market Value, By Product Type, 2022-2031 (US$ Million)

Table 9 Global Osteoporosis Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Osteoporosis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Osteoporosis Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Osteoporosis Drugs Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Osteoporosis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 14 North America Osteoporosis Drugs Market Value, By Product Type, 2022-2031 (US$ Million)

Table 15 North America Osteoporosis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Osteoporosis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Osteoporosis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 18 South America Osteoporosis Drugs Market Value, By Product Type, 2022-2031 (US$ Million)

Table 19 South America Osteoporosis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Osteoporosis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Osteoporosis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 22 Europe Osteoporosis Drugs Market Value, By Product Type, 2022-2031 (US$ Million)

Table 23 Europe Osteoporosis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Osteoporosis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Osteoporosis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Osteoporosis Drugs Market Value, By Product Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Osteoporosis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Osteoporosis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Osteoporosis Drugs Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Osteoporosis Drugs Market Value, By Product Type, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Osteoporosis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 F. Hoffmann-La Roche: Overview

Table 33 F. Hoffmann-La Roche: Product Portfolio

Table 34 F. Hoffmann-La Roche: Key Developments

Table 35 Novartis AG: Overview

Table 36 Novartis AG: Product Portfolio

Table 37 Novartis AG: Key Developments

Table 38 Merck & Co.: Overview

Table 39 Merck & Co.: Product Portfolio

Table 40 Merck & Co.: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Eli Lilly and Co. (Lilly): Overview

Table 45 Eli Lilly and Co. (Lilly): Product Portfolio

Table 46 Eli Lilly and Co. (Lilly): Key Developments

Table 47 Amgen Inc.: Overview

Table 48 Amgen Inc.: Product Portfolio

Table 49 Amgen Inc.: Key Developments

Table 50 Radius Health, Inc.: Overview

Table 51 Radius Health, Inc.: Product Portfolio

Table 52 Radius Health, Inc.: Key Developments

Table 53 Teva Pharmaceutical Industries Ltd.: Overview

Table 54 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 55 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 56 GSK Plc: Overview

Table 57 GSK Plc: Product Portfolio

Table 58 GSK Plc: Key Developments

Table 59 AbbVie Inc.: Overview

Table 60 AbbVie Inc.: Product Portfolio

Table 61 AbbVie Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 2 Global Osteoporosis Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 3 Global Osteoporosis Drugs Market Share, By Product Type, 2023 & 2031 (%)

Figure 4 Global Osteoporosis Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Osteoporosis Drugs Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Osteoporosis Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Bisphosphonates Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 8 RANK Ligand Inhibitors Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 9 Selective Estrogen Receptor Modulators Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 10 Parathyroid Hormone Analog Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 11 Strontium Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 12 Calcitonin Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 13 Anti-Sclerostin Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 14 Others Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 15 Global Osteoporosis Drugs Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 16 Branded Product Type in Global Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 17 Generics Product Type in Global Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 18 Global Osteoporosis Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacy Distribution Channel in Global Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 20 Retail Pharmacy Distribution Channel in Global Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 21 Online Pharmacy Distribution Channel in Global Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 22 Global Osteoporosis Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 24 Asia-Pacific Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 25 Europe Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 26 South America Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 27 Middle East and Africa Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 28 North America Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 29 North America Osteoporosis Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 30 North America Osteoporosis Drugs Market Share, By Product Type, 2023 & 2031 (%)

Figure 31 North America Osteoporosis Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 32 North America Osteoporosis Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 33 South America Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 34 South America Osteoporosis Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 35 South America Osteoporosis Drugs Market Share, By Product Type, 2023 & 2031 (%)

Figure 36 South America Osteoporosis Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 37 South America Osteoporosis Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 38 Europe Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 39 Europe Osteoporosis Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 40 Europe Osteoporosis Drugs Market Share, By Product Type, 2023 & 2031 (%)

Figure 41 Europe Osteoporosis Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 42 Europe Osteoporosis Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 43 Asia-Pacific Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 44 Asia-Pacific Osteoporosis Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 45 Asia-Pacific Osteoporosis Drugs Market Share, By Product Type, 2023 & 2031 (%)

Figure 46 Asia-Pacific Osteoporosis Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 47 Asia-Pacific Osteoporosis Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 48 Middle East & Africa Osteoporosis Drugs Market Value, 2022-2031 (US$ Million)

Figure 49 Middle East & Africa Osteoporosis Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 50 Middle East & Africa Osteoporosis Drugs Market Share, By Product Type, 2023 & 2031 (%)

Figure 51 Middle East & Africa Osteoporosis Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 52 F. Hoffmann-La Roche: Financials

Figure 53 Novartis AG: Financials

Figure 54 Merck & Co.: Financials

Figure 55 Pfizer Inc.: Financials

Figure 56 Eli Lilly and Co. (Lilly): Financials

Figure 57 Amgen Inc.: Financials

Figure 58 Radius Health, Inc.: Financials

Figure 59 Teva Pharmaceutical Industries Ltd.: Financials

Figure 60 GSK Plc: Financials

Figure 61 AbbVie Inc.: Financials

세계 골다공증 치료제 시장 – 2023-2030

Global Osteoporosis Drugs Market - 2023-2030